# antibody-glycosylation-penetrance

**Empirically-validated glycosylation penetrance tables for antibody variable domains, with independent refutation of the Melo-Braga H/Q blocker rule.**

[![License: MIT](https://img.shields.io/badge/License-MIT-yellow.svg)](https://opensource.org/licenses/MIT)

---

## The Problem

ML tools like RFdiffusion generate antibody sequences without considering post-translational modifications. Van de Bovenkamp et al. (2016) showed that 15-25% of circulating IgG carries Fab glycosylation, acquired through somatic hypermutation. When ML tools recapitulate these sequons without the evolutionary selection context, the resulting antibodies may have:

- Heterogeneous glycoform populations
- Altered binding kinetics  
- Reduced stability
- Immunogenicity risk
- Manufacturing variability

**This dataset provides the empirical penetrance values needed to triage ML-designed sequences for glycosylation liability.**

---

## Key Findings

### 1. The H/Q Blocker Rule is Only Half Right

Melo-Braga et al. (2024) claimed both histidine and glutamine at the X-position block glycosylation completely. Our analysis of 19,265 PDB structures shows **Q is not a blocker**:

![X-residue penetrance ranking](x_residue_penetrance_20260127.png)

| X-Residue | Melo-Braga | This Study | Status |
|-----------|------------|------------|--------|
| **H** | 0/6 (0%) | 0/81 (0%) | âœ… Confirmed blocker |
| **Q** | 0/11 (0%) | 2/79 (2.5%) | âŒ **Not a blocker** |
| **I** | Highest | 16.4% | âœ… Confirmed high risk |

---

### 2. Our Dataset is Independent

To ensure this isn't an artifact of re-analyzing Melo-Braga's data, we compared datasets directly:

![Dataset comparison](melo_braga_vs_validation_20260127.png)

**Critical:** Both Q glycosylation events occur in our decontaminated dataset (PDBs not in Melo-Braga's study). The penetrance difference (35% vs 5%) reflects opposite ascertainment biasesâ€”they sought glycosylated structures, crystallographers avoid them.

---

### 3. VL Chains Have Higher Risk Than VH

A novel finding not reported by Melo-Braga:

![Chain type analysis](vh_vs_vl_analysis_20260127.png)

| Chain | Sequons | Glycosylated | Penetrance | 
|-------|---------|--------------|------------|
| VH | 1,511 | 65 | 4.3% |
| VL | 692 | 48 | 6.9% |

**Odds ratio: 0.60 (p = 0.012)** â€” VL has ~60% higher baseline risk than VH.

---

### 4. Regional Hotspots with Bias Correction

Framework regions (especially FR1 and FR4) show highest penetrance. Error bars show sensitivity to ascertainment bias correction:

![Regional penetrance](penetrance_by_region_sensitivity_20260127.png)

**Risk hierarchy:** FR1 > FR4 > FR3 >> CDR1 > CDR3 > CDR2 â‰ˆ FR2

---

## Risk Summary

```
BLOCKED (<1%):     H, P
LOW (1-3%):        K, W, N, G, Y, V, Q(VH)
MODERATE (3-10%):  Q(VL), A, F, S, M, C, T, L
HIGH (10-20%):     D, R, I
EXTREME (>20%):    I in FR1 (40%), position 20 (37%)
```

**Third position effect:** N-X-T (10.2%) >> N-X-S (2.3%) â€” 4.4Ã— higher risk

---

## Quick Start

```python
import pandas as pd

# Load penetrance lookup tables
x_residue = pd.read_csv('data/scanner_x_residue_lookup.csv', index_col=0)
region = pd.read_csv('data/scanner_region_lookup.csv', index_col=0)
chain_x = pd.read_csv('data/scanner_chain_x_lookup.csv', index_col=[0,1])

# Check risk for a sequon with X=Q in VL
risk = chain_x.loc[('VL', 'Q'), 'penetrance']  # Returns 0.043 (4.3%)
```

---

## Repository Contents ðŸš§ðŸš§ (Under Construction)

```
antibody-glycosylation-penetrance/
â”œâ”€â”€ README.md
â”œâ”€â”€ LICENSE
â”œâ”€â”€ paper/
â”‚   â””â”€â”€ intro_methods.md          # Manuscript Introduction & Methods
â”œâ”€â”€ data/
â”‚   â”œâ”€â”€ PDB_validation_FINAL_dataset.parquet    # Complete sequon dataset
â”‚   â”œâ”€â”€ scanner_x_residue_lookup.csv            # X-residue penetrance
â”‚   â”œâ”€â”€ scanner_region_lookup.csv               # Regional penetrance
â”‚   â”œâ”€â”€ scanner_chain_x_lookup.csv              # Chain Ã— X-residue
â”‚   â”œâ”€â”€ scanner_position_lookup.csv             # IMGT position-specific
â”‚   â””â”€â”€ scanner_third_pos_lookup.csv            # S vs T effect
â”œâ”€â”€ notebooks/
â”‚   â””â”€â”€ ALL_Data_penetrance.ipynb               # Full analysis (Colab)
â””â”€â”€ figures/
    â”œâ”€â”€ x_residue_penetrance.png                # Fig 1: X-residue risk
    â”œâ”€â”€ vh_vl_analysis.png                      # Fig 2: Chain effects
    â”œâ”€â”€ penetrance_by_region.png                # Fig 3: Regional risk
    â””â”€â”€ melo_braga_vs_validation.png            # Fig 4: Dataset comparison
```

---

## Methods Summary

1. **PDB Query:** All human antibody structures (X-ray/cryo-EM, â‰¤3.5 Ã… resolution)
2. **Sequon Detection:** N-X-S/T where X â‰  P
3. **Glycosylation Detection:** Carbohydrate residues within 2.0 Ã… of Asn NÎ´
4. **Numbering:** IMGT via ANARCII 2.0.3
5. **Statistics:** Fisher's exact test, Wilson CIs, Bayesian logistic regression (PyMC)

See `paper/intro_methods.md` for full methodology.

---

## Citation

If you use this dataset or findings, please cite:

```bibtex
@misc{antibody_glyco_penetrance_2025,
  author = {[Your Name]},
  title = {Independent Validation of N-linked Glycosylation Penetrance in Antibody Variable Domains},
  year = {2025},
  publisher = {GitHub},
  url = {https://github.com/[username]/antibody-glycosylation-penetrance}
}
```

### Related Work

- Melo-Braga MN et al. (2024) "N-glycosylation in the variable domain of antibodies" â€” the dataset we validate and extend
- van de Bovenkamp FS et al. (2016) "The emerging importance of IgG Fab glycosylation in immunity" â€” biological context for SHM-introduced glycosylation

---

## License

MIT License â€” use freely with attribution.

---

## Contact

**AntibodyML LLC**

Christopher Gaughan, PhD  
ðŸ“§ clgaughan@proton.me  
ðŸ”— LinkedIn
